Inhibitors of proteases and amide hydrolases that employ an α-ketoheterocycle as a key enabling functionality

被引:60
作者
Maryanoff, Bruce E. [1 ]
Costanzo, Michael J. [1 ]
机构
[1] Johnson & Johnson Res & Dev, Vasc Res Team, Spring House, PA 19477 USA
关键词
protease; hydrolase; peptidase; inhibitor; structure-based drug design; ketoheterocycle; transition-state analogue;
D O I
10.1016/j.bmc.2007.11.015
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This article reviews the scientific literature on the application of alpha-ketoheterocycles to the discovery of potent enzyme inhibitors. The alpha-ketoheterocycle functionality provides a moderately electrophilic ketone carbonyl with 'tunable' reactivity, as well as a structural template for introducing new interactions in the enzyme active-site cleft. This type of moiety has served an important role in the design of active-site-directed inhibitors of diverse serine and cysteine proteases, and of fatty acid amide hydrolase ( FAAH). Potent inhibitors have been identified for, inter alia, elastase, thrombin, factor Xa, tryptase, chymase, cathepsin K, cathepsin S, and FAAH. For example, 6e is an orally active inhibitor of human neutrophil elastase that entered human clinical studies, 52h is an orally bioavailable inhibitor of human chymase, and 82m is a FAAH inhibitor with in vivo endocannabinoid-enhancing activity. (C) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1562 / 1595
页数:34
相关论文
共 212 条
  • [1] ADAMS J, 2003, NAT REV CANCER, V5, P417
  • [2] Unique overlap in the prerequisites for thrombin inhibition and oral Bioavailability resulting in potent oral antithrombotics
    Adang, AEP
    de Man, APA
    Vogel, GMT
    Grootenhuis, PDJ
    Smit, MJ
    Peters, CAM
    Visser, A
    Rewinkel, JBM
    van Dinther, T
    Lucas, H
    Kelder, J
    van Aelst, S
    Meuleman, DG
    van Boeckel, CAA
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (20) : 4419 - 4432
  • [3] ADANG AEP, 1999, BIOORD MED CHEM LETT, V9, P2497
  • [4] Nonpeptidic chymase inhibitors: Design and structure-activity relationships of pyrimidinone derivatives based on the predicted binding mode of a peptidic inhibitor
    Akahoshi, F
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (15) : 1191 - 1199
  • [5] Chymase inhibitors and their therapeutic potential
    Akahoshi, F
    [J]. DRUGS OF THE FUTURE, 2002, 27 (08) : 765 - 770
  • [6] Synthesis, structure-activity relationships, and pharmacokinetic profiles of nonpeptidic α-keto heterocycles as novel inhibitors of human chymase
    Akahoshi, F
    Ashimori, A
    Sakashita, H
    Yoshimura, T
    Imada, T
    Nakajima, M
    Mitsutomi, N
    Kuwahara, S
    Ohtsuka, T
    Fukaya, C
    Miyazaki, M
    Nakamura, N
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (08) : 1286 - 1296
  • [7] Peptidyl alpha-keto thiazole as potent thrombin inhibitors
    Akiyama, Y
    Tsutsumi, S
    Hatsushiba, E
    Ohuchi, S
    Okonogi, T
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (05) : 533 - 538
  • [8] Engineering D-amino acid containing novel protease inhibitors using catalytic site architecture
    Annedi, SC
    Biabani, F
    Poduch, E
    Mannargudi, BM
    Majumder, K
    Wei, LH
    Khayat, R
    Tong, L
    Kotra, LP
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (01) : 214 - 236
  • [9] Substrate specificity of glycinamide ribonucleotide transformylase from chicken liver
    Antle, VD
    Liu, DS
    McKellar, BR
    Caperelli, CA
    Hua, M
    Vince, R
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (11) : 6045 - 6049
  • [10] Molecular recognition of protein-ligand complexes: Applications to drug design
    Babine, RE
    Bender, SL
    [J]. CHEMICAL REVIEWS, 1997, 97 (05) : 1359 - 1472